
OneSource Specialty Pharma shares rose 14% to a three-week high of ₹1,589 after reporting strong second-quarter financial results.
Revenue increased 37% year-on-year to ₹516.2 crore, driven by new drug-device combination capacity and successful master services agreements.
The company reaffirmed its fiscal 2028 guidance of $400 million in organic revenue, expecting volume growth in the second half of the year.